Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 89-101

  Swords, Ronan ^a   Mahalingam, Devalingam ^a   Padmanabhan, Swaminathan ^a   Carew, Jennifer ^a   Giles, Francis J ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Chronic myeloid leukemia; Imatinib; Nilotinib

Indexed keywords

ATAZANAVIR; CARBAMAZEPINE; CLARITHROMYCIN; CYTARABINE; DASATINIB; DEXAMETHASONE; IMATINIB; KETOCONAZOLE; MIDAZOLAM; NILOTINIB; PHENYTOIN; RECOMBINANT ALPHA INTERFERON; RITONAVIR;

ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPEREOSINOPHILIC SYNDROME; LEUKOPENIA; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARMACOGENETICS; PLEURA EFFUSION; POINT MUTATION; QT PROLONGATION; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SIDE EFFECT; SKIN PRURITUS; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; VOMITING;

EID: 77953673237     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Faderl S, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-172.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17): 1330-1340.
3. Jemal A, et al. Cancer statistics. CA Cancer J Clin. 2006;56(2) 106-130.
4. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
5. O'Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
6. Hochhaus A, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic Phase (CML-CP) treated with imatinib. Poster presentation at the 2007 American Society of Hematology annual meeting.
7. Silver RT, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Poster presentation at the 2004 American Society of Hematology annual meeting; 2004.
8. Novartis. Online at: http://www.pharma.us.novartis.com/product/pi/ pdf/gleevec-tabs.pdf. 2006.
9. Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-880.
10. Corbin AS, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101(11):4611-4614.
11. Shah NP, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117-125.
12. Azam M, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A. 2006;103(24):9244-9249. (Pubitemid 43902563)
13. Griswold IJ, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26(16):6082-6093.
14. von Bubnoff N, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108(4):1328-1333.
15. von Bubnoff N, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359(9305):487-491.
16. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18(8):1321-1331. (Pubitemid 39136739)
17. Donato NJ, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690-698.
18. Illmer T, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18(3):401-408. (Pubitemid 38425851)
19. Gambacorti-Passerini C, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92(20):1641-1650. (Pubitemid 30807644)
20. Novartis Pharmaceuticals Corporation: East Hanover (NJ). Tasigna (nilotinib capsules): US prescribing information (online). Available form URL: hhtp//www.fda.gov/.
21. Manley PW, et al. Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl. Poster presentation at the 2005 American Society of Hematology annual meeting; 2005.
22. Golemovic M, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11(13):4941-4947. (Pubitemid 41557215)
23. O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505. (Pubitemid 40740783)
24. Weisberg E, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765-1769. (Pubitemid 43882564)
25. Weisberg E, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141. (Pubitemid 40248339)
26. Gleixner KV, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107(2):752-759.
27. Prenen H, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology. 2006;77(1):11-16.
28. Stover EH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005;106(9):3206-3213.
29. Verstovsek S, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006;30(11):1365-1370. (Pubitemid 44307328)
30. Verstovsek S, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006;30(12):1499-1505. (Pubitemid 44573482)
31. Bradeen HA, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332-2338.
32. Kantarjian H, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24): 2542-2551. (Pubitemid 43882350)
33. Kantarjian HM, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-3546.
34. le Coutre P, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834-1839.
35. Ottman O, et al. Nilotinib monotherapy in patients with imatinib-resistant or intolerant Ph+ chronic myeloid leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Poster Presented at the 12th Congress of the European Hematology Associat ion, 2008.
36. Moen MD, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs. 2007;67(2):299-320. (Pubitemid 46259331)
37. Cortes J, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008;22(12):2176-2183.
38. Nicolini F, et al. Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML): Updated Safety Analysis. Poster Presentation at the 12th Congress of the European Hematology Association, 2008.
39. Hochaus A, et al. Minimal Cross Intolerance between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Accelerated Phase (AP). Poster Presentation at the 12th Congress of the European Hematology Association, 2008.
40. Giles F, et al. Nilotinib therapy after dasatinib failure in patients with imatinib resistant or intolerant chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia [abstract no. 0554]. Poster presentation at the 12th Congress of the European Hematology Association (EHA), 2007.
41. Giles F, et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib [abstract no. 7038]. Poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology. 2007.
42. Swords R, et al. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma. 2007;7 Suppl 3: S113-S119. (Pubitemid 46848465)